Applications open for four Alpern Fund grants
The A. Alfred Taubman Medical Research Institute’s Consortium for Stem Cell Therapies (CSCT) seeks proposals for innovative research at the University of Michigan that utilize either human embryonic stem cell (hESC) lines or human induced pluripotent stem cell (hiPSC) lines derived by the CSCT. These grants are made possible from the generous contribution of Robert and Marge Alpern to a capital Fund for Stem Cell Research.
Two grants of $50,000 each will be available for the derivation of new lines (either hESC or hiPSC).
Two grants of $15,000 each will be available to support the transfer, directed differentiation, and phenotypic analysis of existing CSCT-produced disease-specific hESC lines. These lines are unique in that several represent the only existing line(s) for specific single-gene defects available worldwide. These funds can also support basic training, if needed, in pluripotent stem cell maintenance, growth, and characterization. A list of CSCT-derived hESC lines can be found at: http://grants.nih.gov/stem_cells/registry/current.htm.
Applications must be received by Nov. 1, 2012. For complete information about the grants and the application process, click here.
Help Us Make A Difference. Make A Donation That Could Save Lives.
Taubman Science
ALS patient feels great after stem cell transplant
Took part in Phase I of Dr. Eva Feldman's human clinical trial
Ted Harada tells Crain's Detroit Business that nearly nine months after receiving stem cell injections to his spinal cord, improvement persists.
Click here to read the interview
Clinical Trials
The birth of two human clinical trials
The Taubman Institute’s overriding purpose is to discover potential new treatments that can be tested in clinical trials. Watch as two Taubman Scholars explain how they made it happen.
Taubman Science
Institute training video helps physicians overseas
U-M exam method for diabetic nerve damage translated to Mandarin Chinese. The Taubman Institute has produced video of an exam protocol that will help doctors in Asia and elsewhere as they grapple with growing diabetes epidemics and the resulting complications.
news & events
The Latest
-
Dr. Eva Feldman discusses stem cell therapies on Michigan Radio
June 14, 2013 -
2013 Taubman Prize
June 05, 2013 -
Stem cell treatment "dramatically slows ALS" in some patients
May 31, 2013
Taubman Science
Taubman Scholars direct 31 human clinical trials
Science funded by the Taubman Institute has led to 31 current human clinical trials, studying potential therapies for diseases including breast cancer, muscular dystrophy, diabetes and ALS. See the complete list of trials.
People who care
Generous donors fund institute's summer students
Leadership advisory board members fund Tauber Family Student Internship Program
Three future medical scientists will work with Taubman Institute researchers starting in June.
Accomplishments
State leaders laud Taubman Institute accomplishments
Leaders of state and local government visited the Taubman Institute on March 18 to tour Taubman Scholar labs and discuss the potential medical research offers for both improving the health of residents and establishing new jobs and businesses in Michigan.
Donors pitch in to keep brilliant science minds at U-M Video
